Cardiff Oncology, Inc.

NasdaqCM:CRDF Stock Report

Market Cap: US$256.9m

Cardiff Oncology Past Earnings Performance

Past criteria checks 0/6

Cardiff Oncology's earnings have been declining at an average annual rate of -21.5%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 9.7% per year.

Key information

-21.5%

Earnings growth rate

49.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate9.7%
Return on equity-59.4%
Net Margin-8,496.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year

Dec 02
Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year

Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market

Nov 24

Revenue & Expenses Breakdown
Beta

How Cardiff Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CRDF Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-41130
30 Sep 230-41130
30 Jun 230-40140
31 Mar 230-39120
31 Dec 220-39130
30 Sep 220-39140
30 Jun 220-38140
31 Mar 220-34140
31 Dec 210-28120
30 Sep 210-25110
30 Jun 210-23100
31 Mar 210-2490
31 Dec 200-2380
30 Sep 200-2060
30 Jun 200-2060
31 Mar 200-1760
31 Dec 190-1760
30 Sep 190-1760
30 Jun 190-1660
31 Mar 190-1970
31 Dec 180-1980
30 Sep 180-1880
30 Jun 181-18110
31 Mar 181-20110
31 Dec 171-25120
30 Sep 170-31140
30 Jun 170-37160
31 Mar 170-39190
31 Dec 160-39220
30 Sep 160-38220
30 Jun 160-31210
31 Mar 160-31190
31 Dec 150-27140
30 Sep 150-25140
30 Jun 150-27120
31 Mar 150-18100
31 Dec 140-1490
30 Sep 140-1170
30 Jun 140-1080
31 Mar 140-1470
31 Dec 130-1270
30 Sep 130-1760
30 Jun 131-1350
31 Mar 131-1240

Quality Earnings: CRDF is currently unprofitable.

Growing Profit Margin: CRDF is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CRDF is unprofitable, and losses have increased over the past 5 years at a rate of 21.5% per year.

Accelerating Growth: Unable to compare CRDF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRDF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: CRDF has a negative Return on Equity (-59.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.